Αποτελέσματα Αναζήτησης
15 Οκτ 2018 · For men aged 55 to 69 years, the decision to undergo periodic prostate-specific antigen (PSA)–based screening for prostate cancer should be an individual one.
- Prostate Cancer Screening | AAFP
Prostate-Specific Antigen. Although PSA testing has been...
- Prostate Cancer Screening | AAFP
15 Φεβ 2013 · The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)-based screening for prostate cancer.
15 Οκτ 2015 · Prostate-Specific Antigen. Although PSA testing has been used to screen for prostate cancer since 1987, there is no consensus on which threshold should warrant a prostate biopsy. The most commonly...
12 Απρ 2023 · PSA screening for prostate cancer should involve consideration of benefits and risks. Screening is associated with a small reduction in prostate cancer deaths; risks include overdiagnosis and...
19 Μαΐ 2016 · PSA screening is uncommon in most of these countries. 3 There is also speculation that some of the decline is an artifact. 15 The decline in mortality also corresponded with changes in coding causes of death and the use of PSA for assessing progression of prostate cancer.
PSA screening involves weighing the benefits of reducing the rate of metastatic prostate cancer and prevention of prostate cancer death against the known potential harms associated with screening and treatment.
The Canadian Task Force on Preventive Health Care recommends against PSA screening for men aged 55 to 69 years.8 However, the US Preventive Services Task Force recently changed its guidance to say that “the decision about whether to be screened for prostate cancer should be an individual one,” without clearly suggesting for or against ...
